Ken Song (RayzeBio)

Bare­ly two months af­ter un­veil­ing a new breed of ra­dio­phar­ma­ceu­ti­cals, Rayze­Bio brings to­tal haul to $150M

Just be­fore Ver­sant and ven­Bio of­fi­cial­ly took the wraps off Rayze­Bio with $45 mil­lion in launch mon­ey, Ken Song reached out to a few oth­er in­vestors “just to give them an overview.”

He wasn’t nec­es­sar­i­ly look­ing to raise mon­ey im­me­di­ate­ly, the CEO said. Where­as the Se­ries A came to­geth­er most­ly around the con­cept of a new ra­dio­phar­ma­ceu­ti­cal com­pa­ny, Rayze­Bio now had more de­tails and progress around its pipeline to il­lus­trate just what its plat­form can do. But the group — com­pris­ing some firms that were known for their crossover and pub­lic port­fo­lios — be­came so en­thused that, bare­ly two months lat­er, he has $105 mil­lion more to work with.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.